TACR3 and cancer: Significantly, the study has drawn a parallel illustration with mammals by identifying the neurokinin 3 receptor (TACR3) as the mammalian counterpart of the Drosophila receptor, which highlighted TACR3 as a potential therapeutic target for treating cancer-related renal dysfunction in human patients.